Reviewed by the Verita Health Medical Advisory Board

Cellular therapies are among the most discussed and most misunderstood areas of modern medicine. The headlines describe them as breakthroughs; the academic literature describes a field where evidence is evolving, where individual responses vary widely, and where careful clinical oversight matters as much as the therapy itself. For patients researching cellular protocols, the gap between those two pictures can be confusing.

This guide is written for that gap. It explains, in practical terms, how cellular therapies are actually delivered at Verita Health, what the patient pathway looks like from consultation to follow-up, and what the current evidence does and does not support. Verita Health's cellular protocols are delivered from our clinical base in Bangkok, with structured pathways for both local patients and international patients travelling specifically for treatment.

What Cellular Therapy Means in a Clinical Context

Cellular therapy refers to the use of living cells, rather than chemical drugs, as the active component of a treatment. Cells may be sourced from the patient themselves (autologous), from a donor (allogeneic), or from cell lines. They may be infused, injected, or implanted, depending on the protocol.

In a longevity and integrative-medicine setting, cellular therapies are typically used to support immune function, recovery, tissue health, and broader healthspan biomarkers. They sit alongside diagnostics, lifestyle interventions, and other therapeutic modalities rather than as standalone treatments.

Three principles guide how cellular therapy is framed clinically:

• Cellular therapies are biological, not pharmaceutical. Outcomes depend on the patient's own biology, not just the dose.
• Evidence varies by therapy and by indication. Some applications (such as certain bone-marrow-related uses) are well established. Others, including many longevity-focused protocols, are supported by emerging rather than fully established evidence.
• Clinical supervision and monitoring are integral. A cellular protocol delivered without diagnostics and follow-up is not the same intervention as one delivered with them.

The Cellular Therapies Verita Health Delivers

Verita Health's cellular pillar covers four primary protocols. Each is delivered with its own clinical pathway and monitoring framework.

Regenerative Cell Therapy

Regenerative cell therapy uses stem and progenitor cells to support the body's repair processes. The aim is to provide cellular support to tissues under stress from ageing, inflammation, or injury, rather than to replace established medical care for a specific diagnosis.

The clinical pathway typically involves:

• A diagnostic workup to confirm candidacy and identify the markers to monitor
• Cell sourcing and preparation, with strict laboratory protocols
• In-clinic administration under supervised conditions
• A monitoring schedule covering inflammatory, metabolic, and where relevant biological-age markers in the weeks and months that follow

Outcomes vary by individual. Evidence for many longevity-focused regenerative applications is still developing, and the clinical team frames expectations accordingly.

Natural Killer Cell Therapy

Natural Killer (NK) cell therapy focuses on a specific subset of immune cells that play a role in surveillance against abnormal cells, including viral and tumour cells. NK cell protocols may be used to support immune function in patients managing immune-related conditions or recovering from cancer.

Our existing article NK Cells Explained: Your Immune System's Silent Defenders Against Ageing & Disease explores the underlying biology in more detail.

The clinical pathway involves immune profiling, cell preparation, infusion under clinical supervision, and post-infusion monitoring of immune markers. As with all cellular protocols, NK cell therapy is delivered as a complement to standard medical care, not as a substitute for it.

Peptide Therapy

Peptide therapy sits adjacent to cellular therapy. Peptides are short chains of amino acids that act as signalling molecules in the body. Therapeutic peptides are used in clinical contexts ranging from metabolic support to recovery and sleep, depending on the specific peptide and indication.

Peptide protocols at Verita Health are always individualised. The clinical team selects peptides based on the diagnostic workup, prescribes them under supervision, and monitors response over time. Patients should be cautious about peptides obtained outside a clinical setting; quality, sourcing, and dosing all materially affect outcomes and safety.

Hyperthermia

Hyperthermia therapy uses controlled elevation of body temperature to stimulate immune response and cellular stress pathways. It is most commonly used in integrative oncology contexts as a complement to standard cancer care, where the evidence base for combining hyperthermia with chemotherapy or radiotherapy continues to develop.

Hyperthermia is delivered in dedicated clinical sessions with continuous monitoring of vital signs, body temperature, and patient comfort. Like all of Verita Health's cellular and integrative protocols, it is positioned as a complement to standard oncology care, not a substitute.

How a Cellular Protocol Is Delivered: The Five-Stage Pathway

Cellular therapies at Verita Health follow a consistent five-stage clinical pathway. The specific protocol changes; the structure does not.

Stage 1: Diagnostic Workup

Every cellular protocol begins with a comprehensive diagnostic assessment. The aim is to confirm whether the patient is a clinically appropriate candidate, identify the specific biomarkers that the protocol will target, and establish a baseline against which response can be measured.

Diagnostics may include:

• Comprehensive blood panels covering metabolic, inflammatory, hormonal, and immune markers
• Genetic and epigenetic testing where biological-age markers are part of the goal
• Cancer-risk and immune-function profiling for oncology-related protocols, including early cancer detection where indicated
• Specific imaging or organ assessments where the protocol's target tissue requires it

Patients with established medical conditions are also asked to share recent results from their existing medical team, so the cellular protocol is designed in coordination with the care they are already receiving.

Stage 2: Candidacy and Consent

Candidacy is not universal. Some patients are not appropriate candidates for cellular therapies, either because of a specific contraindication, because the diagnostic workup suggests other interventions are a better starting point, or because the available evidence does not support the use being considered.

Where candidacy is confirmed, the clinical team walks the patient through the protocol in detail before any cell preparation begins. This includes the rationale for choosing this protocol, what the evidence does and does not show, the realistic range of outcomes, the contraindications, the schedule, and the monitoring plan. Informed consent is treated as a clinical step in its own right, not a formality.

Stage 3: Preparation and Administration

Cell preparation follows strict laboratory protocols. For autologous protocols, this includes the patient's own cell collection; for allogeneic protocols, it involves cells sourced and prepared under regulated conditions.

Administration takes place at the clinic under supervised conditions. Most cellular infusions are delivered over a defined session, with vital-signs monitoring throughout. Patients are observed after the session to confirm tolerance before being discharged.

For international patients, in-clinic days are usually grouped together to minimise time on the ground. Pre-protocol diagnostics are arranged in advance; administration and immediate post-administration monitoring happen in clinic; longer-term follow-up is delivered remotely.

Stage 4: Post-Protocol Monitoring

Cellular protocols are not single events. Their value depends substantially on what is monitored afterwards, and how the data is interpreted.

Post-protocol monitoring typically includes:

• Repeat blood work at defined intervals, often starting within weeks and continuing across months
• Repeat biological-age or immune-marker testing where these were part of the original goals
• Symptom and functional tracking, where relevant
• Structured clinical reviews to assess what has shifted and whether protocol adjustments are warranted

This stage is often where the biggest difference in outcomes appears between supervised and unsupervised cellular treatment. Monitoring is what allows the team to confirm response, identify non-responders, and adjust the broader healthspan plan accordingly.

Stage 5: Iteration and Coordination

Cellular protocols are usually one part of a broader healthspan or recovery plan. Based on monitoring results, the clinical team adjusts the broader plan: adding or removing supplements, recommending repeat cellular sessions where indicated, integrating other modalities such as hyperbaric oxygen therapy or NAD+ infusions, and coordinating with the patient's primary medical team.

Our existing article From Inflammation to Optimisation: How Cellular Therapies Combat Ageing at Its Root explores the broader rationale for placing cellular interventions within an integrated healthspan plan.

Realistic Outcomes and Considerations

Cellular therapies sit in a clinical area where enthusiasm often outruns evidence. A few honest principles inform how Verita Health frames outcomes.

• Evidence is evolving. For some indications, the evidence base is well established. For many longevity-focused applications, the evidence is still developing. The clinical team is explicit about which is which.
• Outcomes vary by individual. Genetic background, lifestyle, prior medical history, and how engaged the patient remains with monitoring all influence response. Two patients on similar protocols may experience meaningfully different outcomes.
• Cellular therapies complement rather than replace standard care. Patients with established cancer, cardiovascular, neurological, or autoimmune diagnoses should continue working with their existing specialists. The cellular protocol is designed to sit alongside that care.
• Some therapies carry risk. Cellular protocols have contraindications, including certain active malignancies, specific autoimmune conditions, and pregnancy. Candidacy is established during the diagnostic workup, not assumed.
• Marketing language is not clinical evidence. Single-patient testimonials, before-and-after stories, and dramatic outcome claims are not how the clinical team evaluates a therapy. Peer-reviewed evidence and individual biomarker response are.

Patients are encouraged to ask the clinical team direct questions: what does the evidence specifically say about this protocol for someone like me; what would success look like in measurable terms; and how would we know if it is not working.

‍

Frequently Asked Questions

What is the difference between cellular therapy and stem cell therapy?

Cellular therapy is the broader category. It includes any therapy in which living cells are used as the active treatment, including stem cells, immune cells (such as Natural Killer cells), and engineered cells. Stem cell therapy is one type of cellular therapy, focused specifically on cells with the capacity to differentiate into other cell types or to support tissue repair.

How long does a cellular therapy protocol take?

The in-clinic component is usually delivered across one or more focused sessions, depending on the protocol. The full pathway, including diagnostics, candidacy review, administration, and post-protocol monitoring, typically spans several months. Cellular therapies are not single events; their value depends on the diagnostic and follow-up work that surrounds them.

Are cellular therapies safe?

Cellular protocols delivered in supervised clinical settings have a well-characterised safety profile, but they do carry risks. Specific contraindications, individual response variability, and the importance of cell sourcing and laboratory standards all matter. Patients should be cautious about cellular therapies offered outside formal clinical settings, where the same standards may not apply.

Can cellular therapy treat cancer?

Some cellular therapies, including certain immune-cell therapies, are part of established cancer care in specific indications and are delivered in oncology centres under standard medical regulation. The cellular protocols offered in integrative-medicine settings, including at Verita Health, are positioned as complements to standard oncology care, not as substitutes. Patients with cancer should always work with their primary oncology team first.

What does cellular therapy cost at Verita Health?

Cost depends on the specific protocol, the diagnostic workup required, and the monitoring schedule. Because protocols are individualised, the clinical team provides a full plan and cost summary as part of the candidacy and consent stage, before any treatment begins. Patients are encouraged to ask for this in writing and to take time to consider it.

Can international patients access cellular therapies at Verita Health?

Yes. International patients commonly engage through a remote diagnostic workup and candidacy review, followed by an in-clinic visit for administration and immediate post-protocol monitoring, with longer-term follow-up delivered remotely. Travel logistics are planned around the protocol so that diagnostic, treatment, and observation days sit within a single trip where practical.

Considering a Cellular Protocol

Cellular therapies can be a meaningful component of a broader healthspan or recovery plan, but they are most usefully understood as one tool within a structured clinical system rather than as a single intervention. The most useful starting point is rarely "should I have cellular therapy". It is "what does my biology suggest is the most useful next step, and where would cellular therapy fit if it does fit at all".

If you are considering whether cellular therapy may be appropriate, the Verita Health team offers consultations at our Bangkok clinic and supports international patients through remote pre-assessment and in-clinic protocol delivery. A specialist consultation can help establish candidacy honestly and place any cellular protocol within the broader context of your individual goals, history, and biology.

Browse the full range of Verita Health services or book a consultation to begin.

‍